NCT03607552
Non-contrast DWI for Supplemental Screening
StatusActive, Not Recruiting
PhaseNot specified
SponsorUniversity of Washington
Primary completion (estimated)
At risk: Primary completion moved at least 9 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 10 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Sep 2026 to Jul 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 5 words
- Study description expanded, about 6 words
- Site details revised at 1 of 2 sites
- Publications: details revised at 3 of 3 entries
- Notable Primary completion date: Sep 2025 to Sep 2026
- Study completion date: Jul 2028 to Jul 2029
- Notable Primary completion date: Sep 2024 to Sep 2025
- Trial status: Enrolling by Invitation to Active, Not Recruiting
- Enrollment target: estimated 375 to confirmed 269
- Notable Primary completion date: Jul 2023 to Sep 2024v11
- Minor Enrollment target: 275 to 375v8
Show 4 earlier versionsHide 4 earlier versions
- Minor Study sites: 1 to 2v6
- Minor Collaborators expanded, about 4 wordsv4
- Notable Trial status: Active, Not Recruiting to Enrolling by Invitationv3
- Minor Trial status: Enrolling by Invitation to Active, Not Recruitingv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Diffusion sensitization (b value)
Timeframe: 2.5 years
Reader Interpretation strategy
Timeframe: 3.5 years
Specificity
Timeframe: 4.5 years
Sensitivity
Timeframe: 4.5 years
Arms and interventions
Phase 1: Pilot Study Phase
Optimize DWI sequences to maximize spatial resolution, reduce distortion, and increase lesion contrast.
Phase 2: Development Phase
Develop interpretation tools to optimize diagnostic performance for detecting cx on DWI.
Phase 3: Reader Performance Phase
Test the performance of the optimized DWI approach for detecting clinically and mammographically-occult cancer in women with dense breasts.
Devices: Non-contrast DWI, Non-contrast MRI
Sites
2 sites in 1 country